Gut microbes can change the route by which NAD⁺ precursors are processed, but that does not establish that taking NR or NMN improves digestive health. Animal tracing studies, experiments with human microbial samples and small human trials offer complementary evidence about metabolism. They do not all measure the same thing, and none of the studies below demonstrates a general treatment for gut symptoms. [1][2][3][4]
NR and NMN are precursors: the body can use material derived from them to make NAD⁺. The NR-versus-NMN comparison covers their basic relationship. Here the question is what happens between swallowing a precursor and measuring a change in blood.
Keep three kinds of evidence separate
| Study and participants | Design and outcome | Finding | Main limit |
|---|---|---|---|
| Kim / Chellappa studies [1][2] | Animal experiments and isotope tracing | Microbes transform precursors and exchange metabolites with host tissues. | Mechanistic animal results do not establish human symptom benefits. |
| Twin study; 20 BMI-discordant pairs [3] | Five months of NR; main cohort open label | Microbial composition and other biological measures changed; metabolic health did not improve. | Limited placebo comparison; no general gut-symptom treatment result. |
| Christen et al.; n = 65 [4] | Fourteen-day randomized open-label human study plus ex vivo experiments | NR and NMN comparably raised circulating NAD⁺; microbial experiments supported a proposed pathway. | Blood biomarkers and laboratory fermentation are not clinical gut-health outcomes. |
The route is more complicated than a capsule-to-cell arrow
A simplified supplement diagram often shows an intact precursor entering a cell and becoming NAD⁺. The mouse studies demonstrate additional routes. Chellappa and colleagues used isotope tracing to show exchange between host tissues and intestinal microbes: host-derived nicotinamide could reach the gut, microbes could convert it to nicotinic acid, and the host could use that material for NAD synthesis. [2]
Kim and colleagues found that orally delivered NMN could undergo microbial deamidation and enter a different synthesis pathway in animals. Antibiotic treatment changed that process. This is a mechanistic observation in an experimental setting, not a reason for a person to take antibiotics or alter prescribed treatment to influence a supplement response. [1]
The useful model is a network: precursor ingestion, absorption and breakdown, microbial conversion, and host reuse of resulting metabolites. Not every molecule follows the same path. That complexity makes absolute claims about “direct delivery” difficult to support without measurements of the actual formulation.
What the 65-person human trial adds
Christen and colleagues compared NR, NMN, nicotinamide and placebo in a randomized, open-label study of 65 healthy participants over fourteen days. NR and NMN produced similar sustained increases in circulating NAD⁺, whereas nicotinamide showed a different, more acute pattern. This was a metabolism study, not a comparison of symptom relief or long-term health. [4]
Separate experiments fermented the compounds with human microbiota outside the body and tested effects in blood samples. Those experiments supported a proposed gut-dependent model. They did not directly trace every step of that proposed pathway inside each trial participant. The distinction between an in-person trial and an ex vivo experiment matters even when both appear in the same paper.
The study was short and open label. Researchers excluded two participants from their modified intention-to-treat analysis because they received the wrong investigational product. These details do not erase the blood findings, but they help define the question the study can answer. It cannot tell us whether a particular microbiome profile predicts who will feel better after a supplement. [4]
A changed microbiome is not automatically a healthier gut
The five-month twin study gave NR to 20 pairs of genetically identical twins who differed in body mass index. It reported changes in NAD metabolism, muscle biology and gut microbial composition. Both members of those BMI-discordant pairs received NR; the main cohort was not a large placebo-controlled efficacy trial. A small separate comparison among BMI-concordant pairs does not remove that limitation. [3]
Despite several biological changes, the authors did not find improvement in adiposity or metabolic health. This is a useful warning against treating a microbiome shift as a benefit in itself. To call a shift beneficial for digestion, a study would need relevant outcomes such as a prespecified symptom measure, alongside an appropriate control.
The same caution applies to marketing for liposomal NMN. A different delivery claim does not establish better gut health, and microbiome research does not validate every formulation sold under the precursor’s name.
What a consumer can reasonably conclude
The gut is part of NAD precursor metabolism rather than a passive tube. Human blood measurements support NR and NMN as ways to alter NAD metabolism, and laboratory work helps explain possible routes. How much each microbial route contributes in different people, and whether that produces meaningful digestive benefits, remain separate research questions.
There is no established microbiome test in these studies that tells a buyer which NAD supplement to choose. Nor do they establish that a probiotic combination improves an NR or NMN outcome. For the broader distinction between mechanism and demonstrated benefit, see the evidence guide. Questions about adverse effects and individual health circumstances belong alongside the mechanism, as discussed in the supplement safety review.